Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORB-011 In Patients With Advanced Solid Tumors
NCT05947474Phase 1Completed
- Sponsor
- Orionis Biosciences
- Start
- Aug 2023
- Primary completion
- May 2026
- Modality
- Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ORB-011 in solid tumor, sponsored by Orionis Biosciences. Primary endpoints: Number of Adverse Events at 12 months and Recommended Phase 2 Dose at 12 months. Started Aug 2023; status: completed.
02
Drugs
ORB-011
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05947474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947474.